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OBJECTIVE—A better understanding of the molecular mecha-
nisms underlying the development and progression of diabetic
neuropathy (DN) is essential for the design of mechanism-based
therapies. We examined changes in global gene expression to
deﬁne pathways regulated by diabetes in peripheral nerve.
RESEARCH DESIGN AND METHODS—Microarray data for
24-week-old BKS db/db and db/+ mouse sciatic nerve were ana-
lyzed to deﬁne signiﬁcantly differentially expressed genes (DEGs);
DEGs were further analyzed to identify regulated biological pro-
cesses and pathways. Expression proﬁle clustering was performed
to identify coexpressed DEGs. A set of coexpressed lipid metabo-
lism genes was used for promoter sequence analysis.
RESULTS—Gene expression changes are consistent with struc-
tural changes of axonal degeneration. Pathways regulated in the
db/db nerve include lipid metabolism, carbohydrate metabolism,
energy metabolism, peroxisome proliferator–activated receptor
signaling, apoptosis, and axon guidance. Promoter sequences of
lipid metabolism–related genes exhibit evidence of coregulation
of lipid metabolism and nervous system development genes.
CONCLUSIONS—Our data support existing hypotheses regard-
ing hyperglycemia-mediated nerve damage in DN. Moreover, our
analyses revealed a possible coregulation mechanism connecting
hyperlipidemia and axonal degeneration. Diabetes 60:1981–
1989, 2011
A
ccording to statistics published by the American
Diabetes Association in 2007, 23.6 million peo-
ple, approximately 8% of the U.S. population,
have diabetes and 1.6 million new cases are
diagnosed every year. Type 2 diabetes is the most common
type of diabetes, accounting for 90–95% of all cases, and is
characterized by hyperglycemia, insulin resistance, and
dyslipidemia. In addition, an estimated 57 million American
adults exhibit impaired glucose tolerance, which frequently
develops into type 2 diabetes (1).
The hyperglycemia that deﬁn e sd i a b e t e si sam a j o r
factor in the development of micro- and macrovascular
complications, which severely affect patients’ longevity
and quality of life. Microvascular complications include
retinopathy, nephropathy, and neuropathy. From 60 to 75%
of diabetic patients develop diabetic neuropathy (DN), the
most common and debilitating complication of diabetes (1).
DN is the leading cause of nontraumatic lower-extremity
amputations, and the annual cost of DN management is
e s t i m a t e dt ob em o r et h a n$ 1 0b i l l i o n( 2 ) .
DN results from length-dependent axonal loss affecting
distal portions of extremities ﬁrst and progressing proxi-
mally in a stocking-glove pattern (3). Signs and symptoms
of DN vary, and though both sensory and motor nerve
ﬁbers may be involved, sensory manifestations appear
earlier and are more prevalent. Although development of
DN correlates with the severity and duration of diabetes,
there is a great variability in the onset and progression of
symptoms. Some diabetic patients with poorly controlled
hyperglycemia do not display signs and symptoms of DN,
whereas others with good glycemic control develop DN,
suggesting the involvement of factors besides hyperglycemia.
We contend that a better understanding of the molecular
mechanisms underlying the development and progression of
DN is needed for early diagnosis and intervention as well as
for understanding the failure of existing treatments. Identiﬁ-
cation of potential nonglycemic mechanisms is critical for
better prediction of progression and for designing preventive
therapies (4). For example, obesity and dyslipidemia have
recently been identiﬁed as additional risk factors in the de-
velopment of microvascular complications and may play an
important role in the pathogenesis of DN (5–7).
Because of a mutation in the leptin receptor, BKS db/db
mice are hyperphagic and obese, develop severe type 2
diabetes with marked hyperglycemia, and serve as an ex-
perimental model of type 2 diabetes. These mice develop
diabetes by 4 weeks and DN by 8 weeks of age, with pro-
longed thermal latencies, slowed nerve conduction veloc-
ities (NCVs), and loss of intraepidermal nerve ﬁber (IENF)
density (8,9). In addition, db/db mice exhibit high plasma
triglyceride and lipoprotein levels and may serve as a
model for diabetic dyslipidemia (10). Heterozygous (db/+)
mice do not develop diabetes and are used as nondiabetic
controls in experimental DN (11).
Using DNA microarrays, we compared global gene ex-
pression in the sciatic nerve of db/db mice with that of db/+
mice at 24 weeks of age (20 weeks of diabetes) to study
changes in gene expression in peripheral nerves. Bioinfor-
matic analysis of microarray gene expression data identi-
ﬁes regulated genes and biological processes and provides
new insights into the underlying pathogenesis of the dis-
ease process (12).
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Mice. BKS.Cg-m
+/+Lepr
db/J mice (stock number 000642) were purchased from
Jackson Laboratories (Bar Harbor, ME). Animals were maintained at the
University of Michigan in a pathogen-free environment and cared for following
the University of Michigan Committee on the Care and Use of Animals
guidelines. Mice were given continuous access to food (Purina 5001, Purina
Mills LLC, St. Louis, MO) and water.
Measurement of blood glucose, GHb, cholesterol, and triglyceride
levels. Fasting blood glucose levels were measured every 4 weeks. After
a 6 h fast, tail blood was analyzed using a standard glucometer (One Touch
Proﬁle, LIFESCAN, Inc., Milpitas, CA). At 24 weeks, GHb was measured using
the Helena Laboratories Test Kit, Glyco-Tek afﬁnity column method (Helena
Laboratories Corp., Beaumont, TX). Plasma samples from six mice per group
(db/db and db/+) were pooled, and each pool was analyzed by fast-protein
liquid chromatography. The fractions were assayed for cholesterol and tri-
glyceride levels. These assays were performed as previously published (13).
Assessment of neuropathy. Hind paw withdrawal time and tail ﬂick time
were recorded as measures of thermal latency (14). Sural and sciatic NCVs
were recorded and IENF density in footpads of the mice was measured as
previously described (8,15).
Tissue harvest and RNA preparation. At 24 weeks of age, mice were killed
by sodium pentobarbital overdose and tissues were harvested as previously
described (8). The left sciatic nerve was dissected and stored in 30 mL RNA-
later (Ambion, An Applied Biosystems Business, Austin, TX). Total RNA was
isolated from sciatic nerve using a commercially available silica gel–based
isolation protocol (RNeasy Mini Kit, QIAGEN Inc., Valencia, CA), including an
on-column DNase digestion following the manufacturer’s protocol. RNA
quantity and quality were measured by microﬂuid electrophoresis using the
RNA 6000 Pico LabChip on a 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA).
Affymetrix microarrays. RNA isolated from 10 db/db and 9 db/+ mice was
used for hybridization. Of the total RNA, 75 ng from each sample was ampli-
ﬁed and biotin labeled using the Ovation Biotin-RNA Ampliﬁcation and La-
beling System (NuGEN Technologies Inc., San Carlos, CA) according to the
manufacturer’s protocol. RNA ampliﬁcation and hybridization was performed
in two batches (batch 1: db/db [n = 6], db/+ [n = 5]; batch 2: db/db [n = 4], db/+
[n = 4]) by the University of Michigan Comprehensive Cancer Center Affy-
metrix and Microarray Core Facility using the GeneChip Mouse Genome 430
2.0 Array (Affymetrix, Santa Clara, CA). Hybridization intensities for the probe
features on the chip were detected by laser scan. Image ﬁles were quantiﬁed
using Affymetrix GeneChip software (MAS5) to generate CEL ﬁles.
Data analysis. Body weight, blood glucose and GHb levels, plasma cholesterol
and triglyceride levels, thermal latency measures, IENF density, and NCVs of
the mice from the two groups were compared using a t test. Data for the mice
corresponding to outlier microarrays (see below) were excluded from these
analyses, leaving six db/db and seven db/+ animals.
The Affymetrix CEL ﬁles were processed using a local copy of GenePattern,
a bioinformatics platform from the Broad Institute (16), and standard libraries
from the BioConductor project (http://www.bioconductor.org) and the R
project (http://www.r-project.org). Array quality assessment was performed
using BioConductor Simpleaffy and AffyQCReport packages. Six arrays (two
db/+ and four db/db) identiﬁed as outliers were removed from further analysis
based on the array quality assessment.
Array intensities were normalized with the robust multichip average
method, and probe set to gene mapping was done using the BrainArray
Custom CDF version 12 (17). Log2-transformed data from the two batches of
microarrays were adjusted for batch effect bias using distance weighted
discrimination batch effect correction method (18). Out of 16,394 genes on the
chip, 915 genes with intensity lower than background were removed from
further analysis. Raw and processed microarray data are available in the
National Center for Biotechnology Information Gene Expression Omnibus
repository (http://www.ncbi.nlm.nih.gov/geo, accession number GSE27382).
Intensity-based moderated t test (19) was used to determine signiﬁcant
differential expression, and false discovery rate ,0.05 was used as a threshold
to obtain a list of differentially expressed genes (DEGs). Signiﬁcantly over-
represented biological categories in the DEGs were identiﬁed using the Data-
base for Annotation, Visualization, and Integrated Discovery (DAVID) (12)
version 6.7, and relationships among the categories were visualized using the
ConceptGen gene set relationship mapping tool (20). DEGs were clustered
with Chinese Restaurant Clustering (CRC) (21), and functional enrichment
analysis of DEGs from each of the clusters was performed using DAVID.
The Genomatix (http://www.genomatix.de) literature cocitation network
analysis tool (BiblioSphere) was used to identify pathways and regulatory
networks among the DEGs. Protein–protein interactions (PPIs) among the
DEGs were identiﬁed using the Michigan Molecular Interaction (MiMI) database
(http://mimi.ncibi.org) and visualized using Cytoscape (http://www.cytoscape.
org). Twenty-two DEGs from one CRC cluster, all annotated with “lipid
metabolism,” were selected for promoter sequence analysis. Genomatix Frame-
Worker database was used to search the promoter sequences for over-
represented transcription factor binding site (TFBS) motifs. A region of 1,000
base pair (bp) upstream and 100 bp downstream of a transcription start site
was designated as a promoter region. Promoter sequences of only experi-
mentally veriﬁed transcripts were included in the analysis. A distance of 1–500
bp and a distance variance of 100 bp were permitted between TFBSs.
Real time RT-PCR. The expression levels of ﬁve DEGs (highly upregulated in
the db/db samples) were measured by real time RT-PCR (qRT-PCR) in ﬁve
db/db and six db/+ samples for technical validation of microarray data. The
amount of RNA from each sample was ﬁrst normalized to an endogenous
reference (TATA box binding protein [Tbp]; ΔCT) and then relative to the
control group (ΔΔCT)a n dw a se x p r e s s e da s2
2ΔΔCT.
RESULTS
Diabetes, dyslipidemia, and neuropathy phenotyping.
Table 1 lists phenotyping parameters for the db/db and
db/+ mice measured at 24 weeks of age. The db/db mice
are signiﬁcantly heavier and exhibit higher levels of
fasting blood glucose and GHb than the db/+ mice at
24 weeks of age. Plasma cholesterol and triglyceride
levels are signiﬁcantly elevated in the db/db mice, con-
ﬁrming dyslipidemia in these mice. Thermal latency in the
hind paw and tail is signiﬁcantly increased in db/db mice,
indicative of sensory loss. Both IENF density and sciatic
motor nerve conduction velocity (SMNCV) are signiﬁ-
cantly lower in db/db mice. Increased thermal latency,
loss of IENF density, and decreased SMNCV conﬁrm the
development of DN in the db/db mice at 24 weeks of age.
Differential gene expression. Figure 1 outlines the steps
in the transcriptional analysis of the microarray data. Using
intensity-based moderated t test false discovery rate ,0.05
as a threshold, we identiﬁed 4,017 DEGs; 2,122 genes were
TABLE 1
Phenotyping parameters for the db/db and db/+ mice
Parameter db/db (n =6 ) db/+ (n =7 ) P value
Body weight (g) 51.8 6 4.38 29.6 6 1.64 1.79E-05
Fasting blood glucose (mg/dL) 507.7 6 80.16 148.0 6 33.98 1.57E-03
GHb (%) 12.3 6 0.52 7.1 6 0.56 3.06E-09
Plasma cholesterol (mg/dL) 107 6 18.21 75.8 6 11.89 6.60E-03
Plasma triglyceride (mg/dL) 104.2 6 34.89 56.5 6 9.47 1.91E-02
Hind paw latency (s) 4.0 6 1.09 2.7 6 0.64 3.66E-02
Tail ﬂick latency (s) 5.6 6 0.65 4.1 6 1.00 8.73E-03
IENF density (ﬁbers/mm
2) 27.2 6 2.84 39.8 6 3.13 2.76E-05
Sural NCV (m/s) 15.7 6 5.46 20.6 6 5.03 1.24E-01
SMNCV (m/s) 30.2 6 10.40 48.3 6 4.23 6.26E-03
Diabetes, dyslipidemia, and neuropathy phenotyping parameters measured at 24 weeks of age (mean 6 SD).
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db/db relative to the db/+ samples. Microarray data were
validated using qRT-PCR for 5 selected DEGs, which
demonstrated high correlation between microarray and
qRT-PCR expression levels (Supplementary Table 1).
Functional enrichment. Enrichment analysis identiﬁes
functional categories that have a higher representation in
the regulated genes and, thus, are likely to be active in the
experimental condition. Table 2 lists Gene Ontology (GO)
terms overrepresented in DEGs identiﬁed using DAVID.
Overrepresented biological processes with a higher num-
ber of upregulated genes are cell cycle, lipid metabolic
process, lipid transport, carbohydrate metabolic process,
response to stress, and apoptosis. Biological processes
with a majority of genes downregulated are axonogenesis
and cell adhesion. Overrepresented cellular component
terms are mitochondrion and axon, with a majority of
mitochondrial genes upregulated and a majority of axonal
genes downregulated.
Network analysis. Gene network analysis is useful for
exploring both published and novel gene associations that
may be involved in the process being studied. ConceptGen
is a gene set relation mapping tool that identiﬁes rela-
tionships (signiﬁcant overlap) between an experimental
gene set and curated gene sets in sources such as GO
terms, Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways, and Medical Subject Heading (MeSH) terms (20).
ConceptGen was used to analyze 717 DEGs annotated with
the GO biological processes shown in Table 1. The mouse
gene identiﬁers were converted by ConceptGen Homology
conversion tool to 695 human homologs. Relationship among
selected concepts (GO biological processes, KEGG path-
ways, and MeSH terms) associated with the gene set were
visualized using ConceptGen network graph tool (Fig. 2).
KEGG pathways with signiﬁcant overlap with the DEG set
include fatty acid metabolism, peroxisome proliferator–
activated receptor (PPAR) signaling, and extracellular
matrix–receptor interaction. Concepts related to the DEG
set clustered in three groups: lipid metabolism, apoptosis,
and axonogenesis (Fig. 2).
BiblioSphere generates a network of genes based on
their cocitation in PubMed abstracts and identiﬁes func-
tionally related subnetworks based on known regulatory
relationships and pathway annotation. Figure 3A illus-
trates a BiblioSphere network of DEGs centered on tumor
necrosis factor-a (TNF-a) with gene–gene connections
restricted to expert-curated connections. TNF-a was cho-
sen as the central node because of its importance in type 2
diabetes and lipid metabolism (22). Central nodes of sub-
networks and associated pathways include Hifna (apo-
ptosis), Serpine1 (p53 signaling), App (axonogenesis), Lyn
(Fc ´ RI signaling), and Pparg (PPAR signaling and fatty
acid oxidation) (Fig. 3B).
PPI network of DEGs was constructed using Cytoscape
MiMI plug-in (23). Subnetworks were identiﬁed based on
pathway annotation of genes in MiMI (Fig. 4). Regulated
pathways identiﬁed by PPI network are carbohydrate
metabolism (glycolysis and tricarboxylic acid cycle [TCA]),
energy metabolism (oxidative phosphorylation), lipid me-
tabolism (fatty acid metabolism and glycerolipid metabo-
lism), glutathione metabolism, cell development (cell cycle,
apoptosis, axon guidance, and neurotrophin signaling), cell
communication (cell adhesion and extracellular matrix–
receptor interaction), and signal transduction pathways
FIG. 1. Transcriptional data analysis workﬂow. RNA samples obtained
from the sciatic nerve (SCN) of db/db and db/+ mice were hybridized to
Affymetrix GeneChip microarrays. Data quantiﬁed from scanned
microarrays were analyzed to identify DEGs. Functional enrichment
analysis of DEGs was performed to identify overrepresented biological
categories and pathways. Network analysis identiﬁed functionally re-
lated subgroups of DEGs. Expression proﬁle clustering identiﬁed sub-
groups of coexpressed DEGs. Promoter sequence analysis identiﬁed
overrepresented TFBS modules in the promoter sequences of coex-
pressed genes.
TABLE 2
Overrepresented biological annotation terms
Category Term Number of genes (up/down) Fold enrichment BH P value
GO_BP Cell cycle 191 (126/65) 1.45 2.10E-05
GO_BP Lipid metabolic process 172 (119/53) 1.47 2.40E-05
GO_BP Vesicle-mediated transport 126 (67/59) 1.55 3.20E-05
GO_BP Response to stress 200 (129/71) 1.34 9.36E-04
GO_BP Cell adhesion 164 (70/94) 1.36 2.14E-03
GO_BP Axonogenesis 52 (7/45) 1.72 5.55E-03
GO_BP Apoptosis 160 (99/61) 1.31 1.29E-02
GO_BP Lipid transport 30 (22/8) 1.82 2.27E-02
GO_BP Carbohydrate metabolic process 100 (76/24) 1.2 5.24E-02
GO_CC Axon 33 (6/27) 1.95 2.31E-02
GO_CC Mitochondrion 227 (175/52) 1.91 5.24E-02
Functional terms signiﬁcantly overrepresented in the DEGs are listed. BH P value, Benjamini-Hochberg corrected P value of enrichment in
DAVID; GO_BP, GO biological process; GO_CC, GO cellular component.
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signaling, adipocytokine signaling, Wnt signaling, mitogen-
activated protein kinase [MAPK] signaling, ErbB signaling,
and mammalian target of rapamycin [mTOR] signaling).
Supplementary Table 2 lists DEGs in the pathways reg-
ulated in the db/db nerve. The majority of DEGs in the
glycolysis, TCA, oxidative phosphorylation, fatty acid me-
tabolism, glycerolipid metabolism, mitochondrial fatty acid
elongation, lipid transport, adipocytokine signaling, PPAR
signaling, and apoptosis pathways are upregulated, whereas
most of the axonogenesis-related genes are downregulated
in db/db nerve.
Expression proﬁle clustering and promoter sequence
analysis. Clustering of gene expression proﬁles identiﬁes
potentially coregulated and functionally related subgroups
of genes. CRC, a model-based Bayesian clustering tool,
grouped the DEGs into 18 clusters based on positive as
well as negative correlation among their expression pro-
ﬁles. We performed enrichment analysis for gene sets from
individual clusters to identify overrepresented functional
categories (Supplementary Table 3). Figure 5A illustrates
a cluster of 275 DEGs enriched in “mitochondrion,”“ lipid
metabolic process,” and “axonogenesis.” Gene regulatory
sequence elements are organized into motifs of TFBSs
known as promoter modules, possibly suggesting co-
ordinated regulation by multiple transcription factors
(TFs) (24). We used Genomatix FrameWorker tool to ana-
lyze 41 promoter sequences of 22 genes annotated with
“lipid metabolism” from the above cluster (Fig. 5B)t ol o o k
for signiﬁcantly overrepresented TFBS motifs. Five of these
genes are also annotated with “mitochondrion.” Table 3 lists
the top ﬁve most signiﬁcantly overrepresented promoter
modules consisting of three vertebrate TF matrix families
(groups of functionally similar TFs) (25). The HOXF family
TFs, the HBOX family TF Meox1, the LHXF family TFs, and
the HOMF family TF Msx1 are downregulated, whereas
the ETSF family TFs are upregulated in the db/db nerve
(Supplementary Table 4).
DISCUSSION
How the metabolic dysregulation caused by insulin re-
sistance leads to local nerve ﬁber damage in DN is unclear.
In this study, we performed global gene expression pro-
ﬁling of sciatic nerve from 24-week-old db/db mice, which
exhibit hyperglycemia, dyslipidemia, and DN typical of
type 2 diabetes. We detected alterations in the expression
of genes involved in carbohydrate and lipid metabolism,
lipid transport, stress responses, and apoptosis. Further-
more, promoter sequences of coexpressed lipid metabolism–
related DEGs exhibited signiﬁcantly overrepresented TFBS
motifs and are likely to share a common regulatory mech-
anism relevant to the development of DN.
FIG. 2. ConceptGen network graph of overrepresented concepts visualized in Cytoscape. Network depicting relationships and overlap among
signiﬁcantly overrepresented concepts (GO biological processes, KEGG pathways, and MeSH terms) in the DEGs. Node color represents concept
type, node size represents number of genes in the concept, and thickness of the edge represents gene overlap between concepts.
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BKS db/db mice closely mimic the changes observed in DN
patients (8,9,26–28). However, the db/db mouse model
does not fully duplicate human DN pathology; not all
structural changes observed in human DN are seen in the
db/db mouse (27,29). Duration of diabetes in mice is likely
not long enough for the development of severe long-term
degeneration associated with human DN. The devel-
opment of hyperglycemia and DN in the BKS db/db mice
are considered to be consequences of hyperphagia and
insulin resistance resulting from impaired leptin signaling
in the hypothalamus (8). However, the role of leptin sig-
naling in peripheral nerve is not understood, and whether
leptin receptor mutation and obesity have a compounding
effect on the development of DN in these mice is not known.
Schwann cells (SC) are major contributors to the
mRNA in the sciatic nerve biopsies, with a small contri-
bution coming from axons, epineural ﬁbroblasts, adipo-
cytes, and vascular endothelial cells (30). Our analyses
revealed that genes encoding myelin structural proteins
(P0, Pmp22, Connexin-32, Mag, E-Cadherin, and Peri-
axin), myelin structural lipid synthesis genes (Plp, Elovl6,
and Apolipoprotein D), as well as Sox10, a TF required for
myelination, are downregulated in db/db nerve. Segmental
demyelination has been observed in human DN (31,32);
mouse studies, however, do not report evidence of de-
myelination (27,29). Downregulation of myelin protein-
encoding genes and myelin lipid synthesis genes may
represent SC abnormalities preceding the structural
changes.
The TFs c-Jun and Krox-24, and other genes expressed
by denervated SC to promote axonal regeneration (GAP-43,
Ncam,a n dL1) (33), are downregulated, as are positive
regulators of axonogenesis (Cdh4, Neﬂ, and Mapt) and
axon guidance pathway genes (Netrin G1 and Fyn), sug-
gesting a lack of axonal regeneration. These changes are
consistent with the axonal degeneration observed in mor-
phological studies in the db/db mice (27,29).
Loss of neurotrophic signal in DN may impair nerve
generation and cause dying back of axons (3,34). Neuro-
trophin Ngf; NT-3 receptor TrkC; Gdnf receptors Gfra1,
Gfra3, and Gfra4; neuregulin receptor Erbb; and neuro-
trophin signaling pathway genes (Akt3 and Mapk10) are
downregulated, indicating impaired neurotrophic support
in the db/db nerve. Downregulation of Ngf, TrkC, and GFRa1
is consistent with the results of studies in diabetic rats (35–
37). Other neurotrophins are not differentially regulated in
our data. Some studies in rats with streptozotocin-induced
diabetes report reduced expression of Bdnf, NT-3, NT-4/5,
Igf-I, Igf-II, Cntf, Gdnf, and neurotrophin receptors p75LNGFR
and TrkB approximately 12 weeks after the induction of
diabetes (35–40), whereas others report no change in NT-3
expression in rat sciatic nerve (41). The difference in the
animal models used in the studies (rat model of type 1
diabetes vs. mouse model of type 2 diabetes) may explain
this discrepancy.
The SC marker S100b as well as antiapoptotic genes
(Mapk8ip1 and TGF-b2) are downregulated, whereas
proapoptotic genes (Fas, TNF-a, Casp8,a n dBrca1)a r e
upregulated in the db/db samples (Supplementary Table 2).
The downregulation of SC marker and antiapoptotic genes
along with upregulation of proapoptotic genes suggests SC
apoptosis in db/db nerve; however, no studies to date have
demonstrated SC death in DN.
The causes of axonal and SC degradation in DN are
not well understood, but several hypotheses have been
FIG. 3. BiblioSphere cocitation network of DEGs. Nodes represent genes, node color represents fold change (red/yellow: upregulation; blue:
downregulation). The network is centered at TNF-a. Only shortest paths to the central node are shown for clarity. A: Network of DEGs. B: En-
larged view of the part of the network identiﬁed in A illustrates connections between the central node and other highly connected nodes in the
network. Highly connected nodes in the network include Pparg, App, Serpine1, Hif1a, Irf1, Vdr, Lyn, and Ripk1.
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(3,34). Our analyses indicate increased glucose, energy, and
lipid metabolism in the db/db nerve and support the roles of
hyperglycemia- and hyperlipidemia-induced oxidative stress,
inﬂammatory response, and vascular ischemia in DN. In
addition, our data indicate impaired axonal transport,
neurotrophic signal, cell adhesion, and cell communication.
In this study, we focused on hyperglycemia- and dyslipidemia-
related gene expression changes in the nerve.
Hyperglycemia is a major factor in the development and
progression of DN; current hypotheses suggest the effect
of hyperglycemia is likely to be vascular, metabolic, or
a combination of both (34,42). The metabolic hypothesis
of axonal and SC damage in diabetes suggests that acti-
vation of glucose metabolism pathways in hyperglycemia
results in oxidative stress. In our data, glycolysis, TCA, and
oxidative phosphorylation genes are upregulated (Supple-
mentary Table 2), suggesting activation of glucose and
energy metabolism in the db/db nerve. Upregulation of
oxidative phosphorylation genes and downregulation of
mitochondrial H
+ transporting ATP synthases in the db/db
nerve suggest increased superoxide production (43). The
mitochondrial proton carrier Ucp2, known to be upre-
gulated in response to elevated reactive oxygen species
(ROSs) (44), is highly upregulated; the oxidative stress-
induced growth inhibitor Osgin1 is also upregulated in the
db/db nerve. Upregulation of antioxidant genes (Sod2,
Peroxiredoxins,a n dCatalase) suggests cellular response
to increased ROS production. Edwards et al. (3) hypoth-
esized that increased cellular oxidative stress results in
activation of the Poly (ADP-ribose) polymerase (PARP)
pathway, which in turn induces inﬂammatory responses
in the nerve. Upregulation of PARP, inﬂammatory re-
sponse, and MAPK signaling pathway genes in the db/db
nerve support the PARP pathway–mediated inﬂammatory
response hypothesis. Nuclear factor-kB( N F - kB) induced–
inﬂammatory response is also implicated in demyelination
and axon degeneration (3); however, NF-kB and genes
regulated by NF-kB, such as iNOS, are not differentially
regulated in our data.
The vascular hypothesis of nerve damage in diabetes sug-
gests that activation of glucose metabolism pathways causes
functional and structural changes in the neuronal vasculature
leading to endothelial hypoxia and axonal ischemia (45).
Bradley et al. (46) noted thickening of perineurial cell basal
lamina and increased endoneurial collagenization around
SC in the sural nerve of DN patients. Activation of protein
kinase C by hyperglycemia induces expression of vascular
endothelial growth factor (VEGF)—an angiogenic gene and
permeability factor—inhibits production of nitric oxide and
alters Na
+-K
+-ATPase activity. Activation of glucose metab-
olism pathways induces TGF-b1 and Serpine1 expression,
FIG. 4. MiMI PPI network of DEGs visualized in Cytoscape. Nodes represent genes; edges represent PPIs. A: Entire network. B: Enlarged view of
part of the network identiﬁed in A. Node color represents pathway annotation of genes (for example, blue: oxidative phoshorylation; orange: TCA;
red: apoptosis).
GENE EXPRESSION IN SCIATIC NERVE OF db/db MICE
1986 DIABETES, VOL. 60, JULY 2011 diabetes.diabetesjournals.orgFIG. 5. Gene expression proﬁles generated by CRC. Log2 expression levels in seven db/+ and six db/db samples. A: Expression proﬁle cluster of 275
DEGs enriched in “mitochondrion,”“ lipid metabolic process,” and “axonogenesis.” B: Expression proﬁles of 22 “lipid metabolism” genes selected
for promoter sequence analysis.
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vascular membranes (3). VEGF-C, TGF-b1, and Serpine1
are upregulated; Na
+-K
+-ATPases (Atp1b2 and Atp1b3)
are downregulated in the db/db nerve. Upregulation of
hypoxia-inducible factor Hif1a may indicate cellular re-
sponse to ischemia (47). These changes in gene expression
support the hypothesis of neuronal ischemia and hypoxia.
Imbalance in expression of nitric oxide synthase (Nos)
isoforms has been implicated in diabetic endothelial dys-
function (48); however, these are not differentially expressed
in our data.
Dysregulation of lipid metabolism is implicated in pe-
ripheral neuropathy (7,30,33,49), but the mechanism of its
effect is not well understood. We observed upregulation of
genes expressed by adipocytes (Adiponectin, Perilipin,
Lipin1,a n dLpl), possibly due to increased amounts of ad-
ipose tissue in the epineurium of the db/db nerve. Verheijen
et al. (30) demonstrated that epineurium of adult mouse
sciatic nerve contains adipose-like tissue, and both endo-
neurium and epineurium express lipid metabolism genes;
they suggested that adipocytokine signaling from endo-
neurial adipocytes may regulate lipid metabolism in SC
and axons. Our analysis indicates upregulation of fatty
acid metabolism, glycerolipid metabolism, lipid transport,
PPAR signaling, and adipocytokine signaling genes in the
db/db nerve (Supplementary Table 2).
Vincent et al. (7,50) hypothesized that increased pro-
duction of ROS in hyperglycemia results in lipid perox-
idation and that the formation of oxidized low density
lipoproteins (oxLDL) contributes to the nerve injury in
diabetic dyslipidemia. The apoptotic effect of oxLDL on
vascular endothelial cells and neurons is mediated via
oxLDL receptor (Olr1/LOX-1), which is induced by hyper-
glycemia, ROS, oxLDL, and TNF-a. In vitro studies demon-
strate that binding of oxLDL to Olr1 leads to NADPH oxidase
(Nox) activation, mitochondrial superoxide production, and
neuronal oxidative stress in dorsal root ganglia of mice (50).
oxLDL receptor Olr1 is highly overexpressed and Nox2 is
upregulated in our data, supporting the hypothesis of oxLDL-
induced nerve injury in dyslipidemia, possibly via activation
of Nox. oxLDL also acts on macrophages via scavenger
receptor (Scarb1/CD36) and triggers immune responses
via MAPK and NF-kB signaling pathways (7). In our data,
CD36 and MAPK signaling pathway genes (TNF-a, Il1a,
and TGF-b1) are upregulated, supporting the hypothesis of
CD36-mediated inﬂammatory response in the db/db nerve.
Coexpression of genes suggests shared mechanism
of regulation. DEGs associated with “lipid metabolism,”
“mitochondrion,” and “axonogenesis” clustered together
based on their correlated expression pattern (Fig. 5A). Most
of the lipid metabolism– and mitochondria-associated genes
in the cluster are upregulated, whereas axonogenesis genes
are downregulated. To investigate the potential cor-
egulation mechanism, we analyzed promoter sequences
of 22 DEGs from this cluster annotated with the term “lipid
metabolism”; 5 of these genes are also annotated with “mi-
tochondrion.”
It is interesting that TFs binding to the overrepresented
TFBSs in promoter sequences of lipid metabolism genes
are associated with neuron differentiation, axon guidance,
and immune response, suggesting a possible common reg-
ulatory mechanism in lipid metabolism, stress response,
and axonal degeneration. TFs annotated with “nervous
system development”–related terms are downregulated
in the db/db nerve. The HOXF family, the HBOX family,
and the LHXF family TFs are annotated with “motor axon
guidance” and “regulation of neuron differentiation.” HOMF
family TF Msx1 is annotated with “negative regulation of
vascular endothelial growth factor receptor signaling path-
way” and “neuron differentiation.”“ Immune response”–
associated ETSF family TFs are upregulated in the db/db
nerve (Supplementary Table 4). OCT1 family TF Oct-6, an
SC TF important in myelination (30), is not among the
DEGs.
In conclusion, gene expression changes suggest roles
of multiple etiological factors in the development of DN.
The changes are consistent with pathological character-
istics of DN, such as axonal degeneration and potential
loss of neurotrophic signal. Our ﬁndings support the role
of hyperglycemia-induced oxidative stress and ischemia
in nerve injury. Our results also support the hypothesis
of oxidized lipid–mediated nerve injury and increased mito-
chondrial oxidative stress in dyslipidemia. In addition, our
analyses revealed possible coregulation of lipid metabolism,
stress response, and axonal degeneration genes and
identiﬁed TFs that may modulate this coregulation. Further
investigation into the signal mediated by these TFs is likely
to provide more insight into dyslipidemia-induced nerve
injury.
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